RxDoctor Payments Data

James Harb, MD

Neurology · Amherst, NYNPI 1316435522

Payments from drug & device makers

$137,616in general payments, 2019–2025

Across 510 payments — averaging $269.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurology Practice Consortium GPO, LLC$127K
  • AbbVie$2K
  • Pfizer$894
  • Teva Pharmaceuticals USA, Inc.$867
  • Collegium Pharmaceutical, Inc.$772
  • Tonix Medicines, Inc.$624
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$10,37599%
  • Education$1451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$137,616 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$42,233
Medicare patients
121
Services billed
2,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant50$53,254
Nurtec OdtRimegepant Sulfate36$51,195
UbrelvyUbrogepant43$50,490
Emgality PenGalcanezumab-Gnlm12$13,342
Ajovy AutoinjectorFremanezumab-Vfrm18$12,716
Ajovy SyringeFremanezumab-Vfrm12$8,748
Emgality SyringeGalcanezumab-Gnlm12$8,059
Sumatriptan Succinate29$1,505
Amitriptyline Hcl128$1,380
RizatriptanRizatriptan Benzoate59$718
Tizanidine Hcl54$693
Gabapentin46$438
Propranolol Hcl16$185
Topiramate23$180
Methylprednisolone19$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$2,032$103,74493 claims
PfizerNurtec Odt$894$51,19536 claims
Upsher-smith Laboratories LLCTopiramate$246$18023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.

Other neurology in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →